OKYO OKYO Pharma Ltd: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Stable leadership under Gary Jacob enjoys investor support due to effective cost containment and progress in keratitis research. This EV/EBITDA chart demonstrates a multiple of 0.00, while OKYO Pharma Limited (OKYO) optimizes logistics and testing via third-party contractors. High barriers in the form of molecule patents and strict FDA oversight limit the entry of new players.

To objectively measure the operational efficiency of OKYO Pharma Limited, it is essential for investors to correlate the total enterprise value with its ability to generate earnings before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA multiple trend, one can assess whether the expenditures on drug synthesis automation and ophthalmologist salaries are justified by the company's market capitalization, accounting for its debt load.